肝移植受容者における薬剤レベル変動性と地域的剥奪の関係
Laila Fozouni1, Giuseppe Cullaro2, Ann Lazar3
1Department of Medicine, University of California, San Francisco, California, USA.
Background:
Neighborhood deprivation is associated with adverse outcomes post-liver transplantation in pediatric recipients. We examined the association between neighborhood deprivation index (NDI) and medication level variability index (MLVI), T-cell mediated rejection (TCMR), and graft failure/death in adult liver transplant recipients.
Methods:
We conducted a retrospective cohort study of 1485 adult liver-transplant recipients with >1 year follow-up. NDI was calculated at the census tract level. MLVI, the standard deviation of ≥3 sequential tacrolimus troughs, was dichotomized at MLVI > 2. Hospitalization was analyzed as a binary variable.
Results:
The median age was 65, and 36% were female. In multivariate regression, increased NDI was associated with 20% increased odds of MLVI > 2 between 1-3 years post-transplant (95% CI 1.1-1.3) but not MLVI > 2 between 3-5 years. NDI was associated with a 2.2 times higher hazard of hospitalization between 1-3 years post-transplant (95% CI 1.1-4.4); but not between 3-5 years (HR 1.9, 95% CI 1.0-3.7). NDI was not significantly associated with increased hazard of rejection or graft failure/death. Adjusting for NDI, MLVI > 2 between 1-3 and 3-5 years was associated with a 30% higher hazard of rejection (95% CI 1.1-1.6), and between 1-3 years, a 40% increased hazard of graft failure/death (95% CI 1.2-1.5). We found geospatial hotspots of rejection with positive autocorrelation at Years 1-3 and 3-5 post-transplant (Geary's C 0.97, p = 0.01).
Conclusions:
Efforts to understand why individuals from disadvantaged neighborhoods experience poorer immunosuppression adherence may uncover targeted strategies to improve medication adherence for high-risk groups.
関連する概念動画
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Dosage Regimen: Individualization
Therapeutic Drug Monitoring: Affecting Factors


